impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

One year in review

 

Novel insights into the management of rheumatoid arthritis: one year in review 2024

1, 2, 3, 4, 5, 6, 7, 8, 9

 

  1. Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy.
  2. Rheumatology Division, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  3. Rheumatology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  4. Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, and Rheumatology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  5. Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia, Italy.
  6. Rheumatology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  7. Rheumatology Division, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  8. Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy.
  9. Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza; Rheumatology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, and Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy. carlo.scire@unimib.it

CER17779
2024 Vol.42, N°5
PI 0947, PF 0960
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 38743447 [PubMed]

Received: 17/04/2024
Accepted : 29/04/2024
In Press: 14/05/2024
Published: 14/05/2024

Abstract

New evidence from 2023 has slightly shifted some perspectives on rheumatoid arthritis (RA) management. Glucocorticoids have reaffirmed their role as bridging therapy, while novel studies on JAK inhibitors have examined efficacy, mechanism of action, and their potential in high-risk populations, bolstering our understanding with real-world data. Additionally, among treatment strategies, achieving low disease activity has emerged as comparable to achieving remission in the long term, and new insights have been gained regarding tapering both biological and conventional synthetic DMARDs. Furthermore, novel approaches have been proposed for managing difficult-to-treat RA and pre-RA. In this paper, the reviewers aim to present the most relevant studies published during the last year in the field of RA management.

DOI: https://doi.org/10.55563/clinexprheumatol/166dsf

Rheumatology Article